0 seconds of 49 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
00:49
00:49
 
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Anatara Life’s (ANR) 200-patient Gastrointestinal ReProgramming (GaRP) trial gains momentum, with enrolments back on track after ANR’s festive season break
  • The company expects to finish recruitment for the first phase of the trial early in the second quarter of 2023, with roughly 50 of 90 patients already enrolled
  • This means the company is on track for an interim read-out of results for the irritable bowel syndrome (IBS) study in the third quarter of the year
  • Meanwhile, Antara signs an agreement with healthcare company Mucpharm to use ANR’s licenced technology in mucin-producing cancers and biofilms
  • ANR shares are trading grey at 2.8 cents at 1:37 pm AEDT

Anatara Life’s (ANR) 200-patient Gastrointestinal ReProgramming (GaRP) trial had gained momentum, with enrolments back on track after ANR’s festive season break.

A delay in the recruitment and randomisation of the GaRP trial from mid-December to early 2023 had been anticipated by ANR, although the company said product and placebo trials were back on track again last week.

As such, ANR said it expected to finish recruitment for the first phase of the trial early in the second quarter of 2023, with roughly 50 of 90 patients already enrolled.

This means the company is on track for an interim read-out of results for the irritable bowel syndrome (IBS) study in the third quarter of the year.

Antara said there was a “high prevalence” of digestive disorders requiring relief from both symptoms and the disease process, and the company was focused on building a pipeline of human gastrointestinal health products.

ANR noted there had been no significant tolerance or safety issues to date for its product, and it was experiencing a higher enrolment rate since fixing screen failure inconsistencies.

ANR is currently seeking a site in South Australia for the GaRP-IBS trial stage two while considering the geographical convenience of potential participants.

ANR said the GaRP IBS trial presented a significant market opportunity for non-prescription products used in gastrointestinal disorders and IBS, valued at US$8 billion (A$12.1 billion).

Meanwhile, Anatara has signed an agreement with private healthcare company Mucpharm to allow the utilisation of ANR’s licenced technology for specific fields of interest, including mucin-producing cancers and biofilms.

Mucpharm is a specialised company focused on the treatment of mucin-containing and secreting conditions, and the agreement will provide Anatara with royalties on sales and sub-licencing.

ANR shares are trading grey at 2.8 cents at 1:37 pm AEDT.

ANR by the numbers
More From The Market Online
Tariff concept

Week 14 Wrap: Tariffs tank markets as expected; will Rio Tinto ditch LSE?; EU ETFs soar

Let's start with the obvious one: Trump's wave of "Liberation Day" tariffs have finally come, and…
The Market Online Video

HotCopper Highlights for Week 14 – Mesoblast, Cettire, Neurizon & more!

Good Afternoon and welcome to this edition of HotCopper Highlights, I’m Jonathon Davidson. Let's get into…
Flag of Spain

Elementos publishes robust DFS for Oropesa tin project

Elementos Ltd has seen its shares rise more than 2% following its release of a definitive…
The Market Online Video

Friday’s HotCopper Trends: Mesoblast dodges tariffs, Orthocell’s FDA tick | April 4, 2025

The ASX has been down 1.5% at 7,739 points this morning.